Table 1.
The inputs of the key parameters: the prevalence, transition probability, utility and cost.
| Country | 40–49 | 50–59 | 60–69 | 70–79 | 80+ | Source | |
|---|---|---|---|---|---|---|---|
| Prevalence at model beginning | |||||||
| No disease | Australia | 99.94% | 98.99% | 98.84% | 97.97% | 97.54% | Calculated from Keel et al. [6] |
| Early | Australia | 0.06% | 0.95% | 0.94% | 1.70% | 1.25% | Calculated from Keel et al. [6] |
| Mild | Australia | 0.00% | 0.06% | 0.03% | 0.04% | 0.15% | Calculated from Keel et al. [6] |
| Moderate | Australia | 0.00% | 0.00% | 0.20% | 0.29% | 1.05% | Calculated from Keel et al. [6] |
| Severe | Australia | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | Calculated from Keel et al. [6] |
| No disease | UK | 99.71% | 99.46% | 98.99% | 98.04% | 96.24% | Calculated from Rudnicka et al. [41] |
| Early | UK | 0.29% | 0.48% | 0.46% | 0.81% | 1.15% | Calculated from Rudnicka et al. [41] |
| Mild | UK | 0.00% | 0.07% | 0.07% | 0.14% | 0.33% | Calculated from Rudnicka et al. [41] |
| Moderate | UK | 0.00% | 0.00% | 0.49% | 1.01% | 2.28% | Calculated from Rudnicka et al. [41] |
| Severe | UK | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | Calculated from Rudnicka et al. [41] |
| Annual transition probability | |||||||
| No disease to Early | Australia | 0.02% | 0.28% | 0.28% | 0.29% | 0.29% | Calculated from Keel et al. [6] |
| Early to Mild | Australia | 0.00% | 3.80% | 9.80% | 10.00% | 17.00% | Calculated from Keel et al. [6] |
| Mild to Moderate | Australia | 85% | 85% | 85% | 85% | 85% | [2] |
| Moderate to Severe | Australia | 30% | 30% | 30% | 30% | 30% | [2] |
| No disease to Early | UK | 0.03% | 0.14% | 0.14% | 0.22% | 0.90% | Calculated from Rudnicka et al. [41] |
| Early to Mild | UK | 0.00% | 3.50% | 11.40% | 11.40% | 36.50% | Calculated from Rudnicka et al. [41] |
| Mild to Moderate | UK | 85% | 85% | 85% | 85% | 85% | [2] |
| Moderate to Severe | UK | 30% | 30% | 30% | 30% | 30% | [2] |
| Utility multipliers | Australia value | UK value | Sources |
|---|---|---|---|
| No disease | 1 | 1 | Assumption |
| Early disease stage | 1 | 1 | Assumption |
| Mild | 0.79 | 0.79 | [20] |
| Moderate | 0.64 | 0.64 | [20] |
| Severe | 0.26 | 0.26 | [21] |
| Costs (AUD and GBP respectively) | Australia value | UK value | Sources | |
|---|---|---|---|---|
| Genetic screening test per patient | 350.00 | 175.00 | [42, 43]* | |
| Annual screening costs per patient | 34.43 | 51.28 | Calculated from references [44, 45] | |
| Annual POAG treatment costs per patient | 2012.80 | 563.83 | Calculated from references [46]** | |
| Annual depression treatment per patient | 1405.89 | 2930.41 | Calculated from references [25, 27] | |
| Annual residential aged care facility costs per resident | 66,540.52 | 47,850.90 | [26, 47] | |
| Fall costs per event | 13,466.04 | 2806.00 | Calculated from references [48, 49] | |
| POAG treatment cost weighting by disease stage | ||||
| Early disease stage | 0.934 | 0.934 | [50] | |
| Mild | 1.116 | 1.116 | [50] | |
| Moderate | 1.21 | 1.21 | [50] | |
| Severe | 1.559 | 1.559 | [50] | |
*Based on commercial available tests which utilise genome-sequencing in a standard clinical setting.
**See Appendix10.